PDS Biotech is a pioneering brand dedicated to transforming treatment by harnessing the remarkable power of T cells. Their mission is to create a new generation of targeted cancer immunotherapies and infectious disease vaccines. With a strong focus on leveraging the body's immune system, PDS Biotech has developed proprietary cationic, lipid-based nanoparticle platform technologies called Versamune®.

By combining Versamune® with tumor-associated proteins called antigens, PDS Biotech is able to induce the right type and quantity of potent tumor-infiltrating T cells, which specifically recognize the tumor antigen. One of their innovative products, PDS0301, is a novel tumor-targeting IL-12 immunotherapy that overcomes tumor-induced suppression of the immune system. When used in combination with Versamune®, PDS0301 promotes enhanced infiltration and expansion of T cells within the tumor, leading to more effective immunotherapy.

Additionally, PDS Biotech's Infectimune® platform is utilized in the development of preventive vaccines that induce robust and durable protection against deadly infectious diseases. As a brand committed to saving and improving lives worldwide, PDS Biotech is at the forefront of developing novel immunotherapies that activate T cells and offer targeted treatment solutions. Join their mailing list to stay updated on the latest news and advancements